Request Sample

Global Dorzolamide Hydrochloride Market Research Report 2022

SKU ID : QYR-21590418 | Publishing Date : 31-Aug-2022 | No. of pages : 94

Dorzolamide is a non-bacteriostatic sulfonamide derivative and topical carbonic anhydrase (CA) inhibitor that treats elevated intraocular pressure (IOP) associated with open-angle glaucoma and ocular hypertension. It works by blocking an enzyme in the ciliary process that regulates ion balance and fluid pressure in the eyes.

Due to the COVID-19 pandemic, the global Dorzolamide Hydrochloride market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the forecast period 2022-2028. Fully considering the economic change by this health crisis, the Europe Dorzolamide Hydrochloride market is estimated at US$ million in 2022, while the United States and China are forecast to reach US$ million and US$ million by 2028, respectively. The proportion of the United States is % in 2022, while Chinese percentage is %, and it is predicted that China market share will reach % in 2028, trailing a CAGR of % through the analysis period. As for the Europe Dorzolamide Hydrochloride landscape, Germany is projected to reach US$ million by 2028. and in Asia, the notable markets are Japan and South Korea, CAGR is % and % respectively for the next 6-year period.

On-Line accounting for % of the Dorzolamide Hydrochloride global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While Pregnancy segment is altered to an % CAGR throughout this forecast period and will hold a share about % in 2028.

The global major manufacturers of Dorzolamide Hydrochloride include Alembic Pharms, Bausch and Lomb, FDC, Hi Tech Pharma, Micro Labs, Novartis, Merck and Purdue Pharma, etc. In terms of revenue, the global 3 largest players have a % market share of Dorzolamide Hydrochloride in 2021.

This report focuses on Dorzolamide Hydrochloride volume and value at the global level, regional level, and company level. From a global perspective, this report represents overall Dorzolamide Hydrochloride market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan, etc.

Global Dorzolamide Hydrochloride Market: Segment Analysis

The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2017 to 2028. Understanding the segments helps in identifying the importance of different factors that aid the market growth.



Segment by Type



On-Line

Hospital

Drug Store



Segment by Application



Pregnancy

Lactation

Pediatric Use

Geriatric Use


By Region


North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Russia

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Indonesia

Thailand

Malaysia

Latin America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE



By Company



Alembic Pharms

Bausch and Lomb

FDC

Hi Tech Pharma

Micro Labs

Novartis

Merck

Purdue Pharma

Frequently Asked Questions

This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
  • By product type
  • By End User/Applications
  • By Technology
  • By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.

Contact Information

24/7 Research Support

Phone: +1 424 253 0807

[email protected]